These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 35120131)
1. Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma. Lim W; Nyuykonge B; Eadie K; Konings M; Smeets J; Fahal A; Bonifaz A; Todd M; Perry B; Samby K; Burrows J; Verbon A; van de Sande W PLoS Negl Trop Dis; 2022 Feb; 16(2):e0010159. PubMed ID: 35120131 [TBL] [Abstract][Full Text] [Related]
2. Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole. Nyuykonge B; Lim W; van Amelsvoort L; Bonifaz A; Fahal A; Badali H; Abastabar M; Verbon A; van de Sande W Mycoses; 2022 Jun; 65(6):650-655. PubMed ID: 35398930 [TBL] [Abstract][Full Text] [Related]
3. Novel Compound MMV1804559 from the Global Health Priority Box Exhibits In Vitro and In Vivo Activity against Ma J; Eadie K; Schippers M; Fahal A; Laleu B; Verbon A; van de Sande WWJ Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892422 [TBL] [Abstract][Full Text] [Related]
4. Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim. Lim W; Eadie K; Konings M; Rijnders B; Fahal AH; Oliver JD; Birch M; Verbon A; van de Sande W J Antimicrob Chemother; 2020 Apr; 75(4):936-941. PubMed ID: 31904836 [TBL] [Abstract][Full Text] [Related]
5. Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma. Lim W; Melse Y; Konings M; Phat Duong H; Eadie K; Laleu B; Perry B; Todd MH; Ioset JR; van de Sande WWJ PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006437. PubMed ID: 29698504 [TBL] [Abstract][Full Text] [Related]
6. Inhibiting DHN- and DOPA-melanin biosynthesis pathway increased the therapeutic value of itraconazole in Madurella mycetomatis infected Galleria mellonella. Lim W; Konings M; Parel F; Eadie K; Strepis N; Fahal A; Verbon A; van de Sande WWJ Med Mycol; 2022 Feb; 60(2):. PubMed ID: 35064672 [TBL] [Abstract][Full Text] [Related]
7. Epidemiological cut-off values for itraconazole and ravuconazole for Madurella mycetomatis, the most common causative agent of mycetoma. Nyuykonge B; Siddig EE; Mhmoud NA; Nyaoke BA; Zijlstra EE; Verbon A; Bakhiet S; Fahal AH; van de Sande WWJ Mycoses; 2022 Dec; 65(12):1170-1178. PubMed ID: 36005544 [TBL] [Abstract][Full Text] [Related]
8. Antifungal Activity of Natural Naphthoquinones and Anthraquinones against Madurella mycetomatis. Ma J; Todd M; van de Sande WWJ; Biersack B Chem Biodivers; 2023 May; 20(5):e202300151. PubMed ID: 37067830 [TBL] [Abstract][Full Text] [Related]
9. Naphthylisoquinoline alkaloids: novel agents against the causative pathogens of eumycetoma and actinomycetoma- Khalid SA; Abd Algaffar S; Tajuddeen N; Lombe BK; Bringmann G Antimicrob Agents Chemother; 2024 May; 68(5):e0161223. PubMed ID: 38602413 [TBL] [Abstract][Full Text] [Related]
10. A Falciformispora senegalensis grain model in Galleria mellonella larvae. Ma J; Konings M; Verbon A; van de Sande WWJ Med Mycol; 2023 Aug; 61(8):. PubMed ID: 37451815 [TBL] [Abstract][Full Text] [Related]
11. Combining two antifungal agents does not enhance survival of Galleria mellonella larvae infected with Madurella mycetomatis. Eadie K; Parel F; Helvert-van Poppel M; Fahal A; van de Sande W Trop Med Int Health; 2017 Jun; 22(6):696-702. PubMed ID: 28342219 [TBL] [Abstract][Full Text] [Related]
12. Amphotericin B and terbinafine but not the azoles prolong survival in Galleria mellonella larvae infected with Madurella mycetomatis. Kloezen W; Parel F; Brüggemann R; Asouit K; Helvert-van Poppel M; Fahal A; Mouton J; van de Sande W Med Mycol; 2018 Jun; 56(4):469-478. PubMed ID: 28992315 [TBL] [Abstract][Full Text] [Related]
13. The synthetic synergistic cinnamon oil CIN-102 is active against Madurella mycetomatis, the most common causative agent of mycetoma. Konings M; Eadie K; Lim W; Fahal AH; Mouton J; Tesse N; van de Sande WWJ PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009488. PubMed ID: 34106933 [TBL] [Abstract][Full Text] [Related]
14. Madurella mycetomatis is highly susceptible to ravuconazole. Ahmed SA; Kloezen W; Duncanson F; Zijlstra EE; de Hoog GS; Fahal AH; van de Sande WW PLoS Negl Trop Dis; 2014 Jun; 8(6):e2942. PubMed ID: 24945848 [TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutics: The imidazo[1,2-b]pyridazine scaffold as a novel drug candidate for eumycetoma, a neglected tropical disease. Elkheir LYM; Delaye PO; Penichon M; Eadie K; Mohamed MA; Besson P; Chesnay A; Desoubeaux G; Roger S; van de Sande WWJ; Fahal AH; Enguehard-Gueiffier C Eur J Med Chem; 2024 Nov; 277():116720. PubMed ID: 39142148 [TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal susceptibility of coelomycete agents of black grain eumycetoma to eight antifungals. Ahmed SA; de Hoog GS; Stevens DA; Fahal AH; van de Sande WW Med Mycol; 2015 Apr; 53(3):295-301. PubMed ID: 25631481 [TBL] [Abstract][Full Text] [Related]
17. New species of Madurella, causative agents of black-grain mycetoma. de Hoog GS; van Diepeningen AD; Mahgoub el-S; van de Sande WW J Clin Microbiol; 2012 Mar; 50(3):988-94. PubMed ID: 22205798 [TBL] [Abstract][Full Text] [Related]
18. The in vitro antifungal activity of sudanese medicinal plants against Madurella mycetomatis, the eumycetoma major causative agent. Elfadil H; Fahal A; Kloezen W; Ahmed EM; van de Sande W PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003488. PubMed ID: 25768115 [TBL] [Abstract][Full Text] [Related]
19. The combination of manogepix and itraconazole is synergistic and inhibits the growth of Madurella mycetomatis in vitro but not in vivo. Konings M; Eadie K; Strepis N; Nyuykonge B; Fahal AH; Verbon A; van de Sande WWJ Med Mycol; 2023 Nov; 61(11):. PubMed ID: 37960934 [TBL] [Abstract][Full Text] [Related]
20. Metagenomic detection of eumycetoma causative agents from households of patients residing in two Sudanese endemic villages in White Nile State. Santona A; Mhmoud NA; Siddig EE; Deligios M; Fiamma M; Paglietti B; Bakhiet SM; Rubino S; Fahal AH PLoS Negl Trop Dis; 2022 Aug; 16(8):e0010385. PubMed ID: 36040926 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]